- Home
- VALU vs TNXP Comparison
VALU vs TNXP Comparison
Compare VALU & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VALU
- TNXP
- Stock Information
- Founded
- VALU 1931
- TNXP 2007
- Country
- VALU United States
- TNXP United States
- Employees
- VALU N/A
- TNXP N/A
- Industry
- VALU Investment Managers
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- VALU Finance
- TNXP Health Care
- Exchange
- VALU Nasdaq
- TNXP Nasdaq
- Market Cap
- VALU 366.3M
- TNXP 335.6M
- IPO Year
- VALU N/A
- TNXP N/A
- Fundamental
- Price
- VALU N/A
- TNXP $22.41
- Analyst Decision
- VALU
- TNXP Buy
- Analyst Count
- VALU 0
- TNXP 1
- Target Price
- VALU N/A
- TNXP $70.00
- AVG Volume (30 Days)
- VALU 5.0K
- TNXP 1.1M
- Earning Date
- VALU 09-15-2025
- TNXP 11-11-2025
- Dividend Yield
- VALU 3.20%
- TNXP N/A
- EPS Growth
- VALU 6.17
- TNXP N/A
- EPS
- VALU 2.26
- TNXP N/A
- Revenue
- VALU $34,801,000.00
- TNXP $9,831,000.00
- Revenue This Year
- VALU N/A
- TNXP $14.79
- Revenue Next Year
- VALU N/A
- TNXP $933.49
- P/E Ratio
- VALU $17.25
- TNXP N/A
- Revenue Growth
- VALU N/A
- TNXP N/A
- 52 Week Low
- VALU $32.94
- TNXP $6.76
- 52 Week High
- VALU $57.68
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- VALU 58.97
- TNXP 30.44
- Support Level
- VALU $38.33
- TNXP $23.60
- Resistance Level
- VALU $39.87
- TNXP $29.19
- Average True Range (ATR)
- VALU 0.65
- TNXP 1.63
- MACD
- VALU 0.15
- TNXP 0.12
- Stochastic Oscillator
- VALU 93.13
- TNXP 5.31
About VALU Value Line Inc.
Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.